The antianginal ranolazine mitigates obesity-induced nonalcoholic fatty liver disease and increases hepatic pyruvate dehydrogenase activity

Rami Al Batran(Université de Montréal), John R. Ussher(University of Alberta)
JCI Insight
January 10, 2019
Cited by 18


Related Papers